<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00447863</url>
  </required_header>
  <id_info>
    <org_study_id>0858A2-109</org_study_id>
    <nct_id>NCT00447863</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Bioequivalence of Levonorgestrel/Ethinyl Estradiol Combinations in Cycling Women</brief_title>
  <official_title>An Open-Label, Single-Dose, Randomized, 2-Period, Crossover, Bioequivalence Study to Compare Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg in 2 Dosage Forms With Different Dissolution Characteristics in Healthy, Cycling Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <brief_summary>
    <textblock>
      Levonorgestrel/ethinyl estradiol (LNG/EE) is an investigational drug that is being developed&#xD;
      as an oral contraceptive (birth control pill). The purpose of this trial is to compare&#xD;
      different preparations of LNG/EE by assessing the way they are absorbed into the blood.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>August 2007</start_date>
  <completion_date>August 2007</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the bioequivalence of 2 batches of LNG/EE tablets with different dissolution characteristics</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To obtain additional safety and tolerability data concerning LNG/EE in healthy, cycling women</measure>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Contraception</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levonorgestrel/Ethinyl Estradiol</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women aged 18 to 35 years.&#xD;
&#xD;
          -  Healthy as determined by the investigator on the basis of medical history and&#xD;
             screening evaluations.&#xD;
&#xD;
          -  Must have a history of normal menstrual cycles (24 to 34 days) for the 3-month period&#xD;
             preceding entry into the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any surgical or medical condition that may interfere with the absorption,&#xD;
             distribution, metabolism, or excretion of the test article.&#xD;
&#xD;
          -  Presence, history, or family history of thrombophlebitis, thrombosis, or&#xD;
             thromboembolitic disorders, deep vein thrombosis, pulmonary embolism, or known&#xD;
             coagulopathy.&#xD;
&#xD;
          -  Bethesda system report of low-grade squamous intraepithelial lesion or greater for a&#xD;
             cervical cytologic smear obtained within the last 3 months.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 13, 2007</study_first_submitted>
  <study_first_submitted_qc>March 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2007</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Estradiol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

